Bristol-Myers Squibb Co (BMY) : Shelton Capital Management scooped up 6,512 additional shares in Bristol-Myers Squibb Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 51,455 shares of Bristol-Myers Squibb Co which is valued at $3,848,834.Bristol-Myers Squibb Co makes up approximately 0.34% of Shelton Capital Management’s portfolio.
Other Hedge Funds, Including , Spinnaker Trust boosted its stake in BMY in the latest quarter, The investment management firm added 23,732 additional shares and now holds a total of 31,422 shares of Bristol-Myers Squibb Co which is valued at $2,350,366. Bristol-Myers Squibb Co makes up approx 0.32% of Spinnaker Trust’s portfolio. Destination Wealth Management added BMY to its portfolio by purchasing 4,536 company shares during the most recent quarter which is valued at $346,868. Bristol-Myers Squibb Co makes up approx 0.03% of Destination Wealth Management’s portfolio.Cwm boosted its stake in BMY in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 4,754 shares of Bristol-Myers Squibb Co which is valued at $359,783. Bristol-Myers Squibb Co makes up approx 0.03% of Cwm’s portfolio.Farmers Trust Co reduced its stake in BMY by selling 6,829 shares or 27.54% in the most recent quarter. The Hedge Fund company now holds 17,970 shares of BMY which is valued at $1,359,970. Bristol-Myers Squibb Co makes up approx 0.43% of Farmers Trust Co’s portfolio.
Bristol-Myers Squibb Co opened for trading at $74.96 and hit $75.62 on the upside on Thursday, eventually ending the session at $75.32, with a gain of 0.70% or 0.52 points. The heightened volatility saw the trading volume jump to 34,74,924 shares. Company has a market cap of $125,849 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Initiated by Hilliard Lyons to “Neutral” on May 23, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.